Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing

K. E. Caudle, A. E. Rettie, M. Whirl-Carrillo, L. H. Smith, S. Mintzer, M. T. Lee, T. E. Klein, John Callaghan

Research output: Contribution to journalArticle

80 Citations (Scopus)
Original languageEnglish
Pages (from-to)542-548
Number of pages7
JournalClinical Pharmacology and Therapeutics
Volume96
Issue number5
DOIs
StatePublished - Sep 17 2014

Fingerprint

HLA-B Antigens
Pharmacogenetics
Phenytoin
Anticonvulsants
Genotype
Guidelines
Phenotype
Cytochrome P-450 CYP2C9

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. / Caudle, K. E.; Rettie, A. E.; Whirl-Carrillo, M.; Smith, L. H.; Mintzer, S.; Lee, M. T.; Klein, T. E.; Callaghan, John.

In: Clinical Pharmacology and Therapeutics, Vol. 96, No. 5, 17.09.2014, p. 542-548.

Research output: Contribution to journalArticle

Caudle, K. E. ; Rettie, A. E. ; Whirl-Carrillo, M. ; Smith, L. H. ; Mintzer, S. ; Lee, M. T. ; Klein, T. E. ; Callaghan, John. / Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. In: Clinical Pharmacology and Therapeutics. 2014 ; Vol. 96, No. 5. pp. 542-548.
@article{2a4436778e6d46599d40cd76e06518d3,
title = "Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing",
author = "Caudle, {K. E.} and Rettie, {A. E.} and M. Whirl-Carrillo and Smith, {L. H.} and S. Mintzer and Lee, {M. T.} and Klein, {T. E.} and John Callaghan",
year = "2014",
month = "9",
day = "17",
doi = "10.1038/clpt.2014.159",
language = "English",
volume = "96",
pages = "542--548",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing

AU - Caudle, K. E.

AU - Rettie, A. E.

AU - Whirl-Carrillo, M.

AU - Smith, L. H.

AU - Mintzer, S.

AU - Lee, M. T.

AU - Klein, T. E.

AU - Callaghan, John

PY - 2014/9/17

Y1 - 2014/9/17

UR - http://www.scopus.com/inward/record.url?scp=84908220839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908220839&partnerID=8YFLogxK

U2 - 10.1038/clpt.2014.159

DO - 10.1038/clpt.2014.159

M3 - Article

VL - 96

SP - 542

EP - 548

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -